Clinical trial
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial…
NCT00091195 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00091195 |
|---|---|
| Title | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer |
| Official title | A Phase II Study Of Single Agent Depsipeptide (FK228) In Recurrent, Platinum Sensitive Adeno-Carcinoma Of The Ovary Or Peritoneum |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer |
| Intervention type | Drug |
| Interventions | romidepsin |
| Enrollment | 51 |
| Start date | Sep 1, 2004 |
| Primary completion | Mar 1, 2007 |
| First posted | Sep 9, 2004 |
| Last update posted | Mar 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: